According to the ""

Nov 28, 2021

Friday, Jan 28, 2022 - 20:22:14

Cornell squares up against Canisius

This news has been received from:

All trademarks, copyrights, videos, photos and logos are owned by respective news sources. News stories, videos and live streams are from trusted sources.

mail: [NewsMag]

Cornell (5-1) vs. Canisius (2-4)

Koessler Athletic Center, Buffalo, New York; Monday, 7 p.m. EST

BOTTOM LINE: Cornell and Canisius both look to put winning streaks together . Each squad won at home this past Wednesday. Canisius earned a 76-75 win over Coppin State, while Cornell got a 93-80 win over St.

Francis (Pa.).

LEADING THE CHARGE: Malek Green has averaged 16.2 points and 6.5 rebounds to lead the charge for the Golden Griffins. Armon Harried is also a primary contributor, producing 12.5 points per game. The Big Red are led by Chris Manon, who is averaging 11.3 points and five rebounds.MIGHTY MANON: Manon has connected on 25 percent of the 12 3-pointers he’s attempted and has made 3 of 9 over his last five games. He’s also made 65.2 percent of his foul shots this season.

PASSING FOR POINTS: The Big Red have recently used assists to create baskets more often than the Golden Griffins. Canisius has an assist on 52 of 90 field goals (57.8 percent) over its previous three games while Cornell has assists on 68 of 101 field goals (67.3 percent) during its past three games.

DID YOU KNOW: Canisius has made 10.8 3-pointers per game this season, which is second-best among MAAC teams. The Golden Griffins have averaged 13.7 3-pointers per game over their last three games.


For more AP college basketball coverage: and


This was generated by Automated Insights,, using data from STATS LLC,

Copyright © 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.

News Source:

Tags: college basketball canisius field goals the big red

Who is Matthew Reeves?

Next News:

China Claims Its First mRNA Vaccine Is 95% Effective Against Coronavirus

China’s state-run Global Times on Wednesday cited early clinical trials to claim the mRNA coronavirus vaccine developed by Chinese military scientists and biotechnology firms is up to 95-percent effective.

The Phase I clinical trial, published by the Lancet, was preliminary and very small – it was conducted in December 2020 and involved only 120 people, and it tested antibody levels in the body, not actual exposure to Chinese coronavirus and its variants.

The trial found seroconversion rates of 80 to 95 percent in test subjects within 15 to 30 days after a second injection of the vaccine, called ARCoVAX.

Developed by the Chinese Academy of Military Sciences, the Yunnan Walvax Biotechnology company, and a recently-founded mRNA technology firm called Suzhou Abogen Biosciences, ARCoVAX uses “messenger RNA” techniques similar to Western vaccines produced by companies such as Pfizer and Moderna. 

mRNA vaccines are supposed to teach the human body how to manufacture antibodies to fight off an infection without actually introducing virus cells into the bloodstream. China’s previous vaccines, such as Sinovac, use the older inactivated-virus technique of injecting the patient with dead or neutralized virus cells to induce the desired antibody response.

China claimed extremely high rates of effectiveness for its older products, but they proved highly unreliable when used anywhere the Chinese Communist Party could not control the flow of information about their effectiveness. Some third-party countries eventually began recommending Western products for “booster shots” after coronavirus infections surged among people who were inoculated with Chinese vaccines.

Last summer, Chinese scientists claimed their inactivated-virus vaccines should be more effective than mRNA technology. In December 2021, they claimed a third injection of their old vaccines was among the most effective defenses in the world against the Omicron variant. But on Wednesday, the Global Times quoted Chinese scientists who said mastering mRNA technology is “very important for China, not only to control the COVID pandemic but as treatment in cancer and rare diseases.”

According to the Global Times, the Lancet study demonstrated ARCoVAX has “good safety levels,” with “no serious adverse reactions” reported – aside from a bit of “pain, itch and redness in the injection site, fever, headache, fatigue or malaise, muscle and joint pain, diarrhea, and chills,” of mild to moderate severity.

Later in the article, the authors admitted those fevers might be a problem:

According to The Lancet’s report, adverse events were graded according to the guidelines for vaccine clinical trials issued by the National Medical Products Administration. In China, about 50 percent of participants had grade 3 fever after the first inoculation, and 88 percent of participants in the 25 micrograms group did so after the second shot. When adverse events were graded according to the guidelines for vaccine clinical trials issued by the US FDA, 30 percent of participants had grade 3 fever in the 15 micrograms group. 

In comparison, the incidence of grade 3 fever in the same 30 micrograms group in adults aged 18 to 55 years was zero in the US, 8 percent in Germany and 17 percent in China.

CNN reported in December that China seemed on the verge of authorizing Western mRNA vaccines during last summer’s Delta variant outbreak, but mysteriously delayed regulatory approval, remaining tight-lipped even when another outbreak erupted on the eve of the Beijing Winter Olympics. Chinese officials have also refused to discuss how effective any of their older vaccine products are against the Omicron variant.

The implication is that China is reluctant to admit its vaccines are inferior, even at the risk of coronavirus cases spreading unnecessarily through its population, and looks to be gambling on domestic mRNA products like ARCoVAX coming to the market soon. Production facilities for ARCoVAX are reportedly ready to begin pumping out 200 million doses a year, as soon as approval is given, while established companies like the state-owned Sinopharm are working on mRNA products as well.

Other News

  • Poll: Rand Paul Holds Dominant Lead in Kentucky General Election
  • Poll: Most Voters Oppose Picking Supreme Court Justices Based on Race and Gender
  • Poll: Biden Support Plummets in New Hampshire as 60% Disapprove
  • Mask-or-vaccine mandate in New York extended to mid-February, Hochul says
  • Poll: Joe Biden Receives an F from over 1/3 of Voters for His First Year in Office
  • Poll: Plurality Say States Should Return to Pre-Pandemic Voting Laws
  • Almost Half of Newsmax and OAN Viewers Have Confidence in Dr. Fauci: Poll
  • Poll points to COVID-19 fatigue problem for Biden
  • Youngkin underwater on handling of coronavirus in Virginia: PPP poll
  • Thrill kill professor who was caught in Bay Area is sent to prison for murder
  • James Carville Goes to Bat for Manchin: People ‘B*tching’ About Him Cant See ‘Political Reality’
  • Child vaccine rates alarmingly low as doctors contend with rise in COVID pediatric cases.
  • Bidenflation: Feds Favorite Inflation Measure Soared 5.8% in 2021, Worst in 39 Years
  • Biden would beat both Trump and DeSantis if the presidential election was held today: Joe would get 43% of the vote in head-to-head matchup with the Donald compared to 41% if he was facing the Florida governor, poll finds
  • Key inflation gauge rose 5.8 percent in 2021, most in 39 years
  • COVID-19: Positivity Rate Down Again In CT, 225 New Deaths Reported; Latest Breakdown Of Cases
  • The Hills Morning Report - Democrats sense opportunity with SCOTUS vacancy
  • Restaurant Database Says Seated Dining in Minneapolis Down 76 Percent Since 2019
  • Attorney General Miyares Announces Rule to Cut His Offices Student Debt Collection Fees to 15 Percent